Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition
Ottawa, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The global pharmaceutical market to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR, while India’s pharmaceutical market recorded 17.1% year-over-year growth, highlighting the expanding opportunities in innovative medicines, generics, biologics, advanced manufacturing, and global market expansion a study by Towards Healthcare sister firm of Precedence Research.
Fill out the form for relevant samples, case studies, and examples @ https://www.towardshealthcare.com/download-sample/5341
The global pharmaceutical market is entering a period of strategic transformation as demand for medicines expands alongside investment in biologics, specialty drugs, oncology treatments, advanced therapies, and AI-enabled drug development. At the same time, pharmaceutical companies are reassessing manufacturing locations, international market exposure, pricing strategies, and portfolio priorities in response to regulatory changes and evolving healthcare demand.
Recent industry developments add important context to this forecast. India’s pharmaceutical market recorded 17.1% year-over-year growth in September 2026, while pharmaceutical companies continue to pursue high-value product development, manufacturing expansion, licensing agreements, and technology partnerships. These developments indicate that future growth will depend not only on overall demand but also on companies’ ability to differentiate their portfolios, improve operational resilience, and identify attractive markets.
Pharmaceutical Market Data Snapshot
Source for global market estimates: Towards Healthcare Pharmaceutical Market Research. India’s September growth reflects reported domestic industry performance.
What the Latest Market Data Indicates
The projected increase from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 represents an expansion of approximately USD 1.34 trillion in annual market value over the forecast period. This creates opportunities across drug development, manufacturing, contract services, distribution, and commercialization.
However, the growth opportunity is not evenly distributed. Pharmaceutical companies must distinguish between established high-revenue categories and faster-evolving opportunities in biologics, biosimilars, precision medicine, specialty treatments, and advanced drug delivery.
Three strategic conclusions emerge from the market outlook:
Schedule a meeting: Book a Meeting with the Expert Team
Segment and Regional Intelligence
North America accounted for 36% of the global pharmaceutical market in 2025. The region benefits from substantial healthcare expenditure, advanced research infrastructure, established pharmaceutical commercialization networks, and demand for innovative therapies.
Asia Pacific is projected to grow faster than the global market, with a forecast CAGR of 7.02% through 2034. China’s pharmaceutical market is projected to increase from USD 93.11 billion in 2026 to USD 183.66 billion by 2035, representing a 7.84% CAGR.
These regional differences create distinct priorities. North America remains important for commercialization, product differentiation, and specialty medicines, while Asia Pacific presents opportunities in manufacturing, generics, biosimilars, healthcare access, and localized product strategies. Companies expanding internationally need country-level assessments that consider market potential alongside regulatory requirements, competition, pricing, and distribution.
Latest Pharmaceutical Industry News and Company Developments
India’s pharmaceutical market records strong growth
India’s pharmaceutical market grew 17.1% year over year in September 2026, with sales reaching approximately ₹253 billion. Unit growth reached 5.4%, indicating that increased sales were supported by higher volumes rather than price increases alone.
The second quarter of fiscal 2027 recorded sales of approximately ₹746.1 billion, representing 14.7% year-over-year growth. Oncology recorded 29.4% growth, while vitamins, minerals and nutritionals increased 22.2%, anti-diabetic medicines grew 21.2%, and cardiac therapies increased 20.4%.
This performance creates opportunities for domestic manufacturers, distributors, and international companies evaluating India. It also reinforces the importance of therapy-level demand analysis, competitor benchmarking, and product prioritization rather than relying exclusively on aggregate market growth.
Biocon advances its oncology commercialization strategy
Biocon has finalized a global settlement and licensing agreement with Genentech concerning its cancer medicine Pebrilzo. The agreement resolves ongoing legal disputes and establishes a pathway for planned launches in different markets, subject to regulatory approvals. European Union and UK launches are targeted for early 2027, with a US launch planned for the third quarter of 2028.
The development highlights how intellectual property agreements, licensing arrangements, and launch timelines can influence the commercial value of pharmaceutical assets. Companies evaluating oncology portfolios should monitor legal status, geographic rights, approval requirements, launch readiness, and competitive positioning.
AI-driven drug discovery attracts major investment
On October 13, 2026, Zealand Pharma and Generate Biomedicines announced a collaboration to develop AI-designed protein treatments for obesity and metabolic diseases. The agreement is valued at up to USD 1.2 billion, including an initial USD 30 million payment and potential milestone payments linked to development progress.
The partnership illustrates how pharmaceutical innovation is increasingly shaped by collaboration between established drug developers and technology-focused biotechnology companies. AI-enabled discovery is creating opportunities in target identification, molecule design, candidate selection, and development prioritization, although clinical success and regulatory approval remain uncertain.
For pharmaceutical decision-makers, the commercial question is not simply whether a company uses AI, but whether its technology produces differentiated candidates, credible clinical evidence, scalable manufacturing, and a viable route to commercialization.
Manufacturing investment becomes a strategic priority
Pharmaceutical companies are continuing to invest in domestic production, specialized manufacturing, and supply-chain resilience. In India, Aragen Life Sciences began operations at a high-potency manufacturing platform in Hyderabad in October 2026. The 15,000-square-foot facility has an annual production capacity of 500–600 kg of active pharmaceutical ingredients.
Separately, Zydus Sunshine Lifesciences announced a USD 20 million agreement associated with a pharmaceutical plant in Sri Lanka, with its first phase focused on oral solid dosage forms for the local market.
These developments highlight opportunities for contract manufacturers, suppliers, equipment providers, and pharmaceutical companies seeking regional production capabilities. Facility intelligence, production capacity, technology capabilities, customer relationships, and expansion plans are becoming essential inputs for procurement and investment decisions.
Regulatory developments increase the importance of compliance intelligence
Pharmaceutical companies must also monitor changes in product approvals, manufacturing inspections, pricing policy, marketing practices, and regulatory oversight.
In India, recent developments have included scrutiny of pharmaceutical marketing practices and consideration of tighter oversight for sterile drug products. Such developments can affect compliance obligations, commercialization practices, and manufacturing requirements.
Companies operating across multiple countries need structured regulatory intelligence to anticipate changes, assess potential operational impacts, and prioritize compliance activities.
Where the Pharmaceutical Market Opportunity Is Emerging
The strongest opportunities are increasingly found at the intersection of product innovation, manufacturing capability, and market access.
Companies should also account for pricing pressure, regulatory uncertainty, supply-chain concentration, clinical-development risk, and competitive launches. Market growth does not guarantee that every product, company, or geographic expansion will generate attractive returns.
How Towards Healthcare Helps Pharmaceutical Companies Make Better Decisions
Towards Healthcare Research & Consulting provides market-specific research and intelligence to support pharmaceutical manufacturers, biotechnology companies, contract development and manufacturing organizations, investors, distributors, and commercial strategy teams.
Master Dataset and Competitive Intelligence
Pharmaceutical-specific datasets can connect companies with their products, therapeutic categories, manufacturing sites, suppliers, geographic presence, partnerships, investments, and commercial developments.
Sales teams can identify prospective customers and partners. Business development teams can map licensing and acquisition opportunities. Strategy teams can compare competitors by portfolio, capabilities, and regional presence. Procurement teams can identify potential suppliers and evaluate manufacturing footprints.
Towards Healthcare Quadrant and Interactive Dashboard
The Towards Healthcare Quadrant can support structured benchmarking of pharmaceutical companies across portfolio breadth, therapeutic focus, geographic reach, manufacturing capabilities, and innovation activity.
The interactive dashboard complements this analysis by helping decision-makers monitor market developments, competitive moves, investments, product launches, and technology changes. Together, these tools can support ongoing strategic reviews and help teams identify shifts that may require action.
Quality & Manufacturing Intelligence
Manufacturing intelligence can cover plant locations, capacity, production technologies, suppliers, operational developments, expansion plans, and relevant quality and regulatory indicators.
This is especially useful for manufacturers evaluating new facilities, CDMOs assessing potential customers, procurement teams diversifying supply, and investors comparing operational capabilities. Customized research can also address market entry, pricing, demand forecasting, supplier mapping, strategic benchmarking, and M&A opportunities.
Continuously Updated Pharmaceutical Market Intelligence
Intelligence can be maintained according to client requirements through monthly, quarterly, six-monthly, or annual updates.
Monthly updates may capture product launches, company announcements, investments, regulatory developments, clinical milestones, pricing changes, and capacity expansions. Quarterly updates can support management reviews and competitive planning, while six-monthly and annual updates can support long-term portfolio strategy, market entry, investment assessment, and manufacturing decisions.
The appropriate frequency depends on the market, product lifecycle, competitive intensity, and decisions the client needs to make.
Access Pharmaceutical Market Research and Intelligence
Explore Towards Healthcare’s pharmaceutical market research for detailed forecasts, segment analysis, regional assessments, and competitive insights.
Related Reports
Partner
Connect With Us
USA: +1 804 441 9344
APAC: +61 485 981 310 | +91 87933 22019 | +65 3105 1271
Europe: +44 7383 092 044
Email: sales@towardshealthcare.com
Follow Towards Healthcare